| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Curcumin | 16 | 2023 | 115 | 4.670 |
Why?
|
| Nanoparticles | 23 | 2025 | 449 | 4.480 |
Why?
|
| Nanomedicine | 7 | 2025 | 52 | 3.810 |
Why?
|
| Neoplasms | 20 | 2025 | 1341 | 3.600 |
Why?
|
| Antineoplastic Agents | 17 | 2025 | 979 | 2.860 |
Why?
|
| Prostatic Neoplasms | 15 | 2022 | 1068 | 2.650 |
Why?
|
| Nanostructures | 5 | 2023 | 158 | 2.320 |
Why?
|
| Drug Delivery Systems | 16 | 2024 | 273 | 2.280 |
Why?
|
| Pancreatic Neoplasms | 14 | 2023 | 206 | 1.820 |
Why?
|
| Drug Carriers | 13 | 2022 | 169 | 1.650 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2020 | 134 | 1.580 |
Why?
|
| Humans | 97 | 2025 | 42163 | 1.480 |
Why?
|
| Cell Proliferation | 22 | 2020 | 1420 | 1.470 |
Why?
|
| Nanotechnology | 5 | 2020 | 176 | 1.450 |
Why?
|
| MicroRNAs | 10 | 2022 | 501 | 1.440 |
Why?
|
| Blood Proteins | 5 | 2017 | 75 | 1.410 |
Why?
|
| Tannins | 3 | 2020 | 10 | 1.390 |
Why?
|
| Xanthones | 2 | 2020 | 6 | 1.340 |
Why?
|
| Cell Line, Tumor | 35 | 2024 | 2598 | 1.300 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 130 | 1.230 |
Why?
|
| Chitosan | 4 | 2025 | 52 | 1.190 |
Why?
|
| Animals | 50 | 2025 | 16695 | 1.100 |
Why?
|
| Mucins | 10 | 2024 | 69 | 1.090 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 479 | 0.960 |
Why?
|
| Deoxycytidine | 4 | 2020 | 35 | 0.960 |
Why?
|
| Nanocomposites | 2 | 2024 | 23 | 0.940 |
Why?
|
| Cell Survival | 7 | 2024 | 934 | 0.910 |
Why?
|
| Alginates | 2 | 2022 | 19 | 0.900 |
Why?
|
| Zinc Oxide | 2 | 2023 | 25 | 0.900 |
Why?
|
| Coumarins | 1 | 2025 | 43 | 0.890 |
Why?
|
| Breast Neoplasms | 5 | 2022 | 1679 | 0.860 |
Why?
|
| Inulin | 1 | 2024 | 2 | 0.860 |
Why?
|
| Immunotherapy | 3 | 2023 | 137 | 0.830 |
Why?
|
| Xenograft Model Antitumor Assays | 15 | 2020 | 339 | 0.830 |
Why?
|
| Amyotrophic Lateral Sclerosis | 4 | 2025 | 55 | 0.810 |
Why?
|
| Surgical Instruments | 1 | 2022 | 7 | 0.800 |
Why?
|
| Reactive Oxygen Species | 4 | 2023 | 518 | 0.780 |
Why?
|
| Magnetics | 3 | 2012 | 43 | 0.760 |
Why?
|
| Apoptosis | 16 | 2022 | 1541 | 0.760 |
Why?
|
| Paclitaxel | 3 | 2019 | 64 | 0.750 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 81 | 0.740 |
Why?
|
| Polyethylene Glycols | 3 | 2011 | 101 | 0.740 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 86 | 0.740 |
Why?
|
| Mice, Nude | 11 | 2020 | 403 | 0.720 |
Why?
|
| beta-Cyclodextrins | 5 | 2016 | 35 | 0.710 |
Why?
|
| Anti-Bacterial Agents | 4 | 2023 | 415 | 0.700 |
Why?
|
| Ferric Compounds | 3 | 2019 | 62 | 0.690 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 62 | 0.680 |
Why?
|
| Benzopyrans | 5 | 2019 | 25 | 0.670 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2020 | 5 | 0.670 |
Why?
|
| Polyglycolic Acid | 5 | 2016 | 48 | 0.650 |
Why?
|
| Particle Size | 7 | 2022 | 267 | 0.620 |
Why?
|
| Lactic Acid | 5 | 2016 | 110 | 0.620 |
Why?
|
| Uterine Cervical Neoplasms | 6 | 2019 | 350 | 0.620 |
Why?
|
| Drug Compounding | 3 | 2020 | 90 | 0.590 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 140 | 0.590 |
Why?
|
| Taxoids | 2 | 2016 | 50 | 0.580 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2016 | 577 | 0.580 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 209 | 0.580 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2023 | 60 | 0.570 |
Why?
|
| Metal Nanoparticles | 4 | 2018 | 227 | 0.560 |
Why?
|
| Prostate-Specific Antigen | 2 | 2016 | 145 | 0.550 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2024 | 290 | 0.540 |
Why?
|
| Mice | 19 | 2023 | 6490 | 0.530 |
Why?
|
| Male | 21 | 2025 | 22779 | 0.500 |
Why?
|
| Dextrans | 1 | 2016 | 28 | 0.490 |
Why?
|
| Erythrocytes | 3 | 2019 | 126 | 0.470 |
Why?
|
| Biomedical Research | 1 | 2020 | 467 | 0.460 |
Why?
|
| Chemical Phenomena | 1 | 2015 | 56 | 0.450 |
Why?
|
| Antiviral Agents | 3 | 2022 | 189 | 0.450 |
Why?
|
| Polyethyleneimine | 2 | 2011 | 9 | 0.440 |
Why?
|
| Hyperthermia, Induced | 3 | 2024 | 27 | 0.430 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 184 | 0.410 |
Why?
|
| Biocompatible Materials | 4 | 2025 | 106 | 0.400 |
Why?
|
| Endocytosis | 5 | 2019 | 117 | 0.400 |
Why?
|
| Chemistry, Pharmaceutical | 4 | 2015 | 93 | 0.400 |
Why?
|
| Signal Transduction | 9 | 2020 | 2111 | 0.400 |
Why?
|
| Technology, Pharmaceutical | 1 | 2013 | 32 | 0.390 |
Why?
|
| Drug Design | 2 | 2011 | 183 | 0.390 |
Why?
|
| Anti-HIV Agents | 4 | 2020 | 475 | 0.370 |
Why?
|
| Cellulose | 1 | 2012 | 23 | 0.360 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 506 | 0.360 |
Why?
|
| Protein Binding | 5 | 2020 | 1076 | 0.350 |
Why?
|
| Neoplasm Metastasis | 5 | 2024 | 233 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2020 | 1112 | 0.330 |
Why?
|
| Cytochrome P-450 Enzyme System | 3 | 2019 | 99 | 0.320 |
Why?
|
| Carcinoma in Situ | 2 | 2019 | 16 | 0.300 |
Why?
|
| Disease Models, Animal | 6 | 2021 | 1554 | 0.290 |
Why?
|
| Blood-Brain Barrier | 2 | 2020 | 167 | 0.290 |
Why?
|
| Triterpenes | 2 | 2019 | 18 | 0.290 |
Why?
|
| Nervous System Diseases | 2 | 2021 | 76 | 0.290 |
Why?
|
| Cell Movement | 7 | 2020 | 640 | 0.280 |
Why?
|
| Tumor Stem Cell Assay | 3 | 2013 | 32 | 0.280 |
Why?
|
| Exosomes | 2 | 2021 | 124 | 0.270 |
Why?
|
| Female | 16 | 2025 | 24018 | 0.270 |
Why?
|
| Ovarian Neoplasms | 2 | 2024 | 406 | 0.260 |
Why?
|
| Tubulin | 2 | 2019 | 94 | 0.260 |
Why?
|
| Adenocarcinoma | 2 | 2022 | 287 | 0.260 |
Why?
|
| Cell Line | 3 | 2023 | 1416 | 0.250 |
Why?
|
| HIV-1 | 3 | 2020 | 747 | 0.240 |
Why?
|
| Surface Properties | 3 | 2018 | 157 | 0.240 |
Why?
|
| beta Catenin | 2 | 2017 | 75 | 0.230 |
Why?
|
| Hemostatics | 1 | 2025 | 10 | 0.230 |
Why?
|
| Glucans | 1 | 2025 | 8 | 0.230 |
Why?
|
| Cell Nucleus | 4 | 2024 | 383 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2018 | 933 | 0.230 |
Why?
|
| Membranes, Artificial | 1 | 2025 | 33 | 0.230 |
Why?
|
| Immunoconjugates | 1 | 2024 | 8 | 0.220 |
Why?
|
| Materials Testing | 4 | 2025 | 99 | 0.220 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2018 | 147 | 0.220 |
Why?
|
| Tablets | 1 | 2024 | 11 | 0.220 |
Why?
|
| Immunologic Factors | 2 | 2021 | 50 | 0.210 |
Why?
|
| Prebiotics | 1 | 2024 | 6 | 0.210 |
Why?
|
| Photochemotherapy | 1 | 2024 | 42 | 0.210 |
Why?
|
| Papillomavirus Infections | 2 | 2019 | 363 | 0.210 |
Why?
|
| Cryopreservation | 1 | 2024 | 33 | 0.210 |
Why?
|
| Quantum Dots | 1 | 2024 | 38 | 0.210 |
Why?
|
| Quinolones | 2 | 2020 | 13 | 0.200 |
Why?
|
| Indocyanine Green | 1 | 2023 | 4 | 0.200 |
Why?
|
| Macrophages | 4 | 2024 | 515 | 0.200 |
Why?
|
| Biopsy, Needle | 1 | 2022 | 59 | 0.200 |
Why?
|
| Carbon | 1 | 2024 | 127 | 0.200 |
Why?
|
| Biological Availability | 2 | 2013 | 115 | 0.190 |
Why?
|
| Pharmaceutical Preparations | 1 | 2024 | 93 | 0.190 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 74 | 0.190 |
Why?
|
| Neurodegenerative Diseases | 1 | 2024 | 138 | 0.190 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2022 | 7 | 0.190 |
Why?
|
| Biopsy | 1 | 2022 | 176 | 0.190 |
Why?
|
| Esophageal Neoplasms | 1 | 2024 | 137 | 0.190 |
Why?
|
| Hemolysis | 3 | 2025 | 59 | 0.190 |
Why?
|
| Drug Synergism | 2 | 2020 | 189 | 0.190 |
Why?
|
| Probiotics | 1 | 2022 | 37 | 0.190 |
Why?
|
| Parkinson Disease | 1 | 2024 | 207 | 0.180 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2021 | 23 | 0.180 |
Why?
|
| Breast | 1 | 2022 | 139 | 0.180 |
Why?
|
| Hep G2 Cells | 1 | 2021 | 62 | 0.180 |
Why?
|
| Stomach Neoplasms | 1 | 2024 | 228 | 0.180 |
Why?
|
| Polymers | 1 | 2022 | 151 | 0.180 |
Why?
|
| Cisplatin | 1 | 2021 | 91 | 0.180 |
Why?
|
| Colonic Neoplasms | 1 | 2023 | 223 | 0.170 |
Why?
|
| Hydrogels | 2 | 2022 | 55 | 0.170 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 26 | 0.170 |
Why?
|
| Treatment Outcome | 3 | 2020 | 1586 | 0.170 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2020 | 19 | 0.170 |
Why?
|
| Cystic Fibrosis | 1 | 2020 | 27 | 0.170 |
Why?
|
| Poloxamer | 2 | 2020 | 13 | 0.170 |
Why?
|
| Pilot Projects | 2 | 2020 | 733 | 0.170 |
Why?
|
| Membrane Potential, Mitochondrial | 3 | 2019 | 89 | 0.170 |
Why?
|
| Resins, Plant | 1 | 2020 | 5 | 0.170 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 26 | 0.170 |
Why?
|
| Integrase Inhibitors | 1 | 2020 | 1 | 0.170 |
Why?
|
| Garcinia | 1 | 2020 | 5 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 14 | 0.170 |
Why?
|
| Drug Costs | 1 | 2020 | 36 | 0.160 |
Why?
|
| DNA Repair | 1 | 2021 | 196 | 0.160 |
Why?
|
| Pancreatitis, Chronic | 1 | 2019 | 6 | 0.160 |
Why?
|
| Protein Interaction Mapping | 1 | 2020 | 64 | 0.160 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 366 | 0.160 |
Why?
|
| Genome, Viral | 1 | 2020 | 118 | 0.160 |
Why?
|
| Benzimidazoles | 1 | 2019 | 41 | 0.160 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 98 | 0.160 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 239 | 0.150 |
Why?
|
| DNA Damage | 1 | 2021 | 358 | 0.150 |
Why?
|
| Anti-Retroviral Agents | 1 | 2020 | 158 | 0.150 |
Why?
|
| Imidazoles | 1 | 2019 | 138 | 0.150 |
Why?
|
| Dietary Supplements | 1 | 2020 | 208 | 0.150 |
Why?
|
| Tubulin Modulators | 1 | 2019 | 18 | 0.150 |
Why?
|
| Protein Kinase C | 1 | 2019 | 124 | 0.150 |
Why?
|
| Intracellular Space | 1 | 2018 | 37 | 0.150 |
Why?
|
| Prostate | 1 | 2020 | 152 | 0.150 |
Why?
|
| Spectrum Analysis | 1 | 2018 | 59 | 0.140 |
Why?
|
| TRPP Cation Channels | 1 | 2018 | 5 | 0.140 |
Why?
|
| Indoles | 1 | 2019 | 178 | 0.140 |
Why?
|
| Biosensing Techniques | 1 | 2020 | 130 | 0.140 |
Why?
|
| Microglia | 1 | 2020 | 204 | 0.140 |
Why?
|
| Photons | 1 | 2018 | 29 | 0.140 |
Why?
|
| Virus Replication | 1 | 2020 | 318 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 502 | 0.140 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 2 | 2025 | 82 | 0.140 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2017 | 24 | 0.140 |
Why?
|
| Histone Deacetylases | 1 | 2018 | 61 | 0.140 |
Why?
|
| Silver | 2 | 2009 | 61 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 233 | 0.130 |
Why?
|
| Chromatography, Liquid | 1 | 2018 | 173 | 0.130 |
Why?
|
| HIV Infections | 3 | 2020 | 2535 | 0.130 |
Why?
|
| Cell Communication | 1 | 2017 | 110 | 0.130 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 230 | 0.130 |
Why?
|
| Microscopy, Electron, Transmission | 3 | 2012 | 160 | 0.120 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 972 | 0.120 |
Why?
|
| Cytosol | 1 | 2016 | 98 | 0.120 |
Why?
|
| X-Ray Diffraction | 3 | 2010 | 66 | 0.120 |
Why?
|
| Repressor Proteins | 1 | 2018 | 267 | 0.120 |
Why?
|
| Static Electricity | 1 | 2015 | 85 | 0.110 |
Why?
|
| Adsorption | 1 | 2015 | 74 | 0.110 |
Why?
|
| Microscopy, Atomic Force | 1 | 2014 | 62 | 0.110 |
Why?
|
| Receptors, Immunologic | 1 | 2014 | 70 | 0.110 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 2011 | 103 | 0.110 |
Why?
|
| Glycoproteins | 1 | 2014 | 127 | 0.100 |
Why?
|
| Smoking | 1 | 2020 | 1019 | 0.100 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 928 | 0.100 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 144 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2013 | 84 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 150 | 0.100 |
Why?
|
| Tissue Distribution | 1 | 2013 | 230 | 0.100 |
Why?
|
| Microscopy, Confocal | 3 | 2019 | 223 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2014 | 884 | 0.100 |
Why?
|
| Models, Molecular | 2 | 2019 | 875 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 3 | 2019 | 284 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 382 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 680 | 0.090 |
Why?
|
| Serum Albumin | 1 | 2011 | 58 | 0.090 |
Why?
|
| Propylene Glycols | 1 | 2010 | 6 | 0.090 |
Why?
|
| Thermogravimetry | 1 | 2010 | 7 | 0.080 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2010 | 36 | 0.080 |
Why?
|
| Adult | 3 | 2025 | 13458 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2011 | 574 | 0.080 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2019 | 16 | 0.080 |
Why?
|
| Microscopy, Electron | 1 | 2010 | 209 | 0.080 |
Why?
|
| Middle Aged | 2 | 2025 | 11819 | 0.080 |
Why?
|
| Gene Knockdown Techniques | 2 | 2020 | 188 | 0.080 |
Why?
|
| Cardiovascular Agents | 1 | 2008 | 24 | 0.070 |
Why?
|
| Tunica Intima | 1 | 2008 | 21 | 0.070 |
Why?
|
| Prognosis | 2 | 2023 | 850 | 0.070 |
Why?
|
| Sirolimus | 1 | 2008 | 70 | 0.070 |
Why?
|
| Escherichia coli | 2 | 2009 | 461 | 0.070 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2008 | 142 | 0.070 |
Why?
|
| Acrylamides | 1 | 2007 | 15 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 261 | 0.060 |
Why?
|
| Mutation | 2 | 2022 | 1169 | 0.060 |
Why?
|
| Cell Cycle | 2 | 2019 | 348 | 0.060 |
Why?
|
| Transfection | 2 | 2019 | 526 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2019 | 973 | 0.060 |
Why?
|
| Nanofibers | 1 | 2025 | 14 | 0.060 |
Why?
|
| Rheology | 1 | 2025 | 51 | 0.060 |
Why?
|
| Neurofilament Proteins | 1 | 2025 | 30 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2020 | 1066 | 0.060 |
Why?
|
| Biological Transport | 2 | 2016 | 201 | 0.060 |
Why?
|
| Pyrroles | 1 | 2024 | 68 | 0.050 |
Why?
|
| Small Molecule Libraries | 1 | 2024 | 60 | 0.050 |
Why?
|
| Photosensitizing Agents | 1 | 2024 | 55 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2024 | 174 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2024 | 130 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2023 | 7 | 0.050 |
Why?
|
| Ferrichrome | 1 | 2022 | 2 | 0.050 |
Why?
|
| Monitoring, Immunologic | 1 | 2022 | 3 | 0.050 |
Why?
|
| Siderophores | 1 | 2022 | 14 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2023 | 84 | 0.050 |
Why?
|
| Tissue Scaffolds | 1 | 2022 | 31 | 0.050 |
Why?
|
| Tissue Engineering | 1 | 2022 | 72 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2022 | 169 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 50 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2025 | 1729 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 332 | 0.040 |
Why?
|
| Plasma | 1 | 2020 | 38 | 0.040 |
Why?
|
| Calcium | 1 | 2023 | 487 | 0.040 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 33 | 0.040 |
Why?
|
| Dosage Forms | 1 | 2019 | 4 | 0.040 |
Why?
|
| Clone Cells | 1 | 2019 | 50 | 0.040 |
Why?
|
| Serum | 1 | 2019 | 17 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 658 | 0.040 |
Why?
|
| Membrane Microdomains | 1 | 2019 | 53 | 0.040 |
Why?
|
| Chemokine CXCL12 | 1 | 2019 | 32 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 97 | 0.040 |
Why?
|
| Mitochondria | 1 | 2023 | 516 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2020 | 237 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2020 | 183 | 0.040 |
Why?
|
| Kinetics | 1 | 2020 | 698 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2019 | 151 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2023 | 722 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2019 | 74 | 0.040 |
Why?
|
| Hela Cells | 1 | 2019 | 370 | 0.040 |
Why?
|
| Chemical Engineering | 1 | 2018 | 1 | 0.040 |
Why?
|
| Viral Load | 1 | 2020 | 344 | 0.040 |
Why?
|
| Porosity | 1 | 2018 | 42 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2018 | 32 | 0.040 |
Why?
|
| Silicon Dioxide | 1 | 2018 | 38 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 491 | 0.040 |
Why?
|
| Quinazolines | 1 | 2018 | 37 | 0.040 |
Why?
|
| Glucose | 1 | 2019 | 242 | 0.040 |
Why?
|
| Catechin | 1 | 2018 | 38 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2018 | 54 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 129 | 0.030 |
Why?
|
| Piperidines | 1 | 2018 | 80 | 0.030 |
Why?
|
| Computational Biology | 1 | 2020 | 324 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2018 | 67 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2018 | 79 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 81 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 59 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 456 | 0.030 |
Why?
|
| Appalachian Region | 1 | 2017 | 5 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2018 | 154 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2018 | 154 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2019 | 400 | 0.030 |
Why?
|
| Ammonia | 1 | 2016 | 22 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2018 | 190 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2023 | 990 | 0.030 |
Why?
|
| Pancreas | 1 | 2016 | 45 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 438 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2016 | 64 | 0.030 |
Why?
|
| Gold | 1 | 2018 | 153 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 454 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2020 | 426 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2017 | 462 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 297 | 0.030 |
Why?
|
| Ovary | 1 | 2016 | 112 | 0.030 |
Why?
|
| Swine | 1 | 2016 | 205 | 0.030 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2016 | 184 | 0.030 |
Why?
|
| Colon | 1 | 2016 | 118 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 228 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2014 | 134 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2018 | 633 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 452 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 196 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1054 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2014 | 420 | 0.030 |
Why?
|
| Risk Factors | 1 | 2021 | 3942 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 649 | 0.020 |
Why?
|
| Aged | 1 | 2025 | 7982 | 0.020 |
Why?
|
| Bacillus | 1 | 2009 | 12 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2008 | 39 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 2008 | 35 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2008 | 138 | 0.020 |
Why?
|
| Silver Nitrate | 1 | 2007 | 5 | 0.020 |
Why?
|
| Surface Plasmon Resonance | 1 | 2007 | 35 | 0.020 |
Why?
|
| United States | 1 | 2017 | 5072 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2008 | 1617 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 1737 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 3701 | 0.010 |
Why?
|